News Headlines Article

Gilead hepatitis C pill reaches $3.48 billion in quarterly sales
San Francisco Chronicle

Despite criticism from insurers and lawmakers, Gilead Sciences said Wednesday its $1,000-a-day hepatitis C pill had improved on its record-setting debut as it reached $3.48 billion in sales last quarter.

The drug, Sovaldi, can cure more than 90 percent of patients with the most common form of hepatitis C, which afflicts 3 million Americans. The therapy was celebrated as the most successful drug launch ever when it brought in $2.3 billion in sales in the first quarter, and it once again surprised analysts who had predicted sales of $2.6 billion in the second quarter.